Plaque Psoriasis

The condition is rare, with limited epidemiological data and no standard treatment.

Advanced practice providers share their perspectives on assessing and grading the disease severity of plaque psoriasis.

Erin Boh, MD, PhD, FAAD, shares insight into clinical manifestations of plaque psoriasis, and panelists emphasize how disease characteristics may be mistaken for signs and symptoms of commonly comorbid diseases.

The clinical and psychological impact of plaque psoriasis on a patient’s overall well-being.

An expert dermatologist, George Han, MD, PhD, provides a brief overview of the pathogenesis of plaque psoriasis and reviews some common environmental triggers.

Dr. Elewski hopes that in the future more clinicians will prescribe biologics such as secukinumab and etancercept for the treatment of psoriasis.

Certain biologics such as infliximab have aided psoriasis patients in the mitigation of symptoms from the COVID-19 virus.

Dr. Elewski speaks of the safety and efficacy of several new and developing therapies, including bimekizumab treatment which has yet to be approved in the United States.

Investigators stated that prolonged maintenance dosing of the monoclonal antibody was preferred by affected patients.

Investigators reported that the efficacy of the medication is supported by a high safety profile, with fleeting and limited adverse events recorded.

Investigators reported that a higher proportion of participants in the abatacept group relapsed between weeks 12 and 40 compared to participants in the ustekinumab group.

Travel issues related to COVID-19 were responsible for the delay in the approval of the Biologics License Application.

Data from the PAUSE clinical trial reveals that more participants experienced psoriasis relapse in the abatacept group than the ustekinumab group.

A recent press release detailed the phase 3 findings that were presented at the virtual conference, which shows that bimekizumab was well-tolerated and efficacious in patients with moderate to severe plaque psoriasis.

The treatment was approved for adult patients with plaque psoriasis in 2018.

Though the severity of the COVID-19 virus did not differ in participants with different dermatological conditions, their conditions were affected in alternate ways.

A rarity in biologic treatments for patients with moderate-to-severe plaque psoriasis, Dr. Miller notes that patients treated with guselkumab recorded overwhelmingly positive PASI scores.

The prevalence of striae distensae was notably higher in psoriasis than atopic dermatitis.

An ongoing study of the IL-17A and IL-17F inhibitor showed patients with moderate to severe plaque psoriasis achieved long-term skin clearance results.

More research is needed to understand the pathogenesis underlying this association.

These results highlight the importance of interventions to address modifiable behaviors and risk factors for these patients.

Secukinumab is the only fully human biologic that directly inhibits IL-17A.

While Janus Kinase inhibitors are a fraction of what’s to come in dermatology, research from AAD VMX 2021 shows they represent the potential of unlocking new capabilities across the field.

Jeffrey Stark, MD, of UCB discusses the promising data being generated by the robust trial program for plaque psoriasis.

The Head of Immunology Medical Affairs at UCB discusses what bimekizumab is and how it works.